| HS Code | 567774 |
| Product Name | CBZ-L-Hydroxyproline |
| Cas Number | 13504-85-3 |
| Molecular Formula | C13H15NO5 |
| Molecular Weight | 265.26 g/mol |
| Synonyms | N-Benzyloxycarbonyl-L-hydroxyproline; Z-L-Hydroxyproline; (2S,4R)-1-[(Benzyloxy)carbonyl]-4-hydroxypyrrolidine-2-carboxylic acid |
| Appearance | White to off-white crystalline powder |
| Purity | ≥98% |
| Melting Point | 105-108 °C |
| Optical Rotation | [α]20/D = -58.0° (c=1, methanol) |
| Solubility | Soluble in methanol, DMSO, and DMF; sparingly soluble in water |
| Storage Conditions | Store at 2-8 °C, protected from light |
| Stability | Stable under recommended storage conditions |
As an accredited CBZ-L-Hydroxyproline factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | CBZ-L-Hydroxyproline is packaged as 5 g in an amber glass vial with airtight seal, protected from light and moisture. |
| Container Loading (20′ FCL) | CBZ-L-Hydroxyproline is loaded as a 20′ FCL in sealed, moisture-proof drums, secured to prevent shifting during transit. |
| Shipping | CBZ-L-Hydroxyproline should be shipped in sealed, moisture-resistant containers at ambient or refrigerated temperatures, away from heat and direct light. Ensure proper labeling, cushioning, and compliance with local regulations. It is typically non-hazardous, but avoid inhalation, skin contact, and prolonged exposure. Keep dry during transit. |
| Storage | Store CBZ-L-Hydroxyproline in a tightly sealed container, protected from light and moisture. Keep in a cool, dry, well-ventilated area, ideally between 2–8°C for long-term stability. Avoid exposure to heat, strong oxidizers, and humidity. Ensure the container remains closed when not in use to preserve purity. |
| Shelf Life | CBZ-L-Hydroxyproline has a shelf life of approximately three years when stored at 2-8°C, desiccated and protected from light. |
In jacketed glass-lined peptide synthesis reactors fitted with pitched-blade impellers and cooled to -15 ± 2 °C, N-carbobenzyloxy-L-hydroxyproline is activated as a mixed anhydride with isobutyl chloroformate and N-methylmorpholine in tetrahydrofuran/dimethylformamide 3:1 v/v. The protected amino acid is charged at 1.05–1.20 molar equivalents relative to the free N-terminal amine of the elongating peptide chain; for N-terminal valine or isoleucine residues, the charge is increased to 1.20–1.30 molar equivalents and the coupling time extended to 6–8 h. The coupling mass is maintained at pH 7.8–8.5 and 10–15 °C for 2–4 h; solvent water content is limited to ≤300 ppm by Karl Fischer titration to avoid mixed-anhydride hydrolysis before amine attack. Activation below -10 °C suppresses oxazolone-mediated racemization; release testing by chiral HPLC limits D-allo-hydroxyproline content to ≤0.3% area. Cbz protection is selected over tert-butoxycarbonyl at the Hyp residue when the target sequence contains acid-labile side-chain protecting groups because hydrogenolytic removal proceeds near pH 6.0–7.0, avoiding the strong acid required for tert-butoxycarbonyl cleavage.
Compliance for this application is anchored to ICH Q7, EU GMP Part II, and 21 CFR 211. Residual solvent testing follows USP <467>; applied limits for common process solvents are methanol ≤3000 ppm, dichloromethane ≤600 ppm, tetrahydrofuran ≤720 ppm, and dimethylformamide ≤880 ppm. Elemental impurities are assessed according to ICH Q3D, and palladium from hydrogenolysis is controlled to ≤10 ppm by Ph. Eur. 2.4.27 or equivalent inductively coupled plasma mass spectrometry after activated-carbon depth filtration. Cbz is not suitable for standard Fmoc-based solid-phase peptide synthesis because its hydrogenolytic removal over palladium is incompatible with resin-bound thiols and some side-chain protecting groups; this compatibility boundary confines the product to solution-phase and Cbz/Bn orthogonal schemes.
Hydrogenolytic deprotection is performed in a pressure-rated hydrogenation vessel at 0.10–0.30 MPa hydrogen using 5% palladium on carbon or 20% palladium hydroxide on carbon in methanol/water 1:1 v/v. Reaction completion is confirmed by thin-layer chromatography and LC-MS; catalyst is removed through a 0.2 μm filter, and the peptide is precipitated from cold methyl tert-butyl ether and vacuum-dried at 30 °C. Terminal product types are solution-phase peptide APIs, primarily collagen-like peptide active substances and anti-fibrotic drug candidates; published data for specific marketed formulations is limited because process details remain in proprietary drug master files.
Manufacture of chiral pyrrolidine organocatalysts from Cbz-L-hydroxyproline begins with O-silylation of the secondary hydroxyl. The charge is 1.05–1.20 molar equivalents of tert-butyldimethylsilyl chloride and 1.10–1.30 molar equivalents of imidazole relative to the 4-hydroxyl group in anhydrous dichloromethane at 0–5 °C. Karl Fischer titration maintains water content below 100 ppm in the reaction mass; above 200 ppm, competing hydrolysis of the silyl chloride yields silanol species and unconverted hydroxyl, generating a diol impurity that co-elutes with the desired protected intermediate in normal-phase HPLC. The quench is performed with 10 wt% ammonium chloride at pH 6.5–7.0, phase separation, and distillation below 40 °C to avoid partial N-Cbz cleavage observed under prolonged thermal stress.
Production-scale equipment for this step typically includes Hastelloy C-22 reactors with nitrogen purge and vacuum-jacketed condensation; controlled addition of silyl chloride in a 500 L reactor requires 45–90 min at 0–5 °C. Quality systems for R&D fine chemicals follow ISO 9001:2015 and REACH; when the downstream catalyst is used in API-related asymmetric synthesis, ICH Q7 applies and residual solvents are tested per USP <467>. Palladium from a subsequent hydrogenolysis step is controlled to ≤10 ppm, and residual silicon is monitored by inductively coupled plasma optical emission spectroscopy.
The resulting protected hydroxyproline intermediate is transformed via esterification and organometallic addition into chiral pyrrolidine organocatalysts and ligands used in asymmetric aldol, Michael, and Diels-Alder reactions. Terminal product types are research- and production-scale chiral organocatalysts supplied to fine chemical and pharmaceutical R&D groups. Published data for specific catalyst configurations is limited because most catalyst routes are held as trade secrets; pilot-scale qualification requires diastereomeric purity ≥99.0:1.0 by supercritical fluid chromatography and moisture exclusion stability over 72 h at 25 °C/60% RH.
| Application segment | Primary standard | Critical purity method | Numerical limit |
|---|---|---|---|
| Solution-phase peptide API | ICH Q7, EU GMP Part II, 21 CFR 211 | USP <467>, ICH Q3D, chiral HPLC | Pd ≤10 ppm; D-allo-Hyp ≤0.3% area |
| Chiral organocatalyst precursor | ISO 9001:2015, REACH | Karl Fischer, ICP-OES, USP <467> | Moisture <100 ppm; Si <150 ppm; Pd ≤10 ppm |
| Cosmetic peptide raw material | EC 1223/2009, REACH | LC-MS/MS, USP <467> | Secondary amine ≤5 ppm; methanol ≤3000 ppm; chloride ≤50 ppm |
| Peptide-linker/bioconjugate | ICH Q7, ICH M7, 21 CFR 211 | USP <467>, ICP-MS | Pd ≤10 ppm; DMF ≤880 ppm |
| Antiviral chiral building block | ICH Q7, ICH Q11 | Chiral HPLC/SFC, USP <467> | Enantiomeric purity ≥99.0% area; Pd ≤10 ppm |
| Custom synthesis reagent | ISO 9001:2015, REACH | HPLC, LC-MS | Assay ≥98.0%; unknown impurities ≤1.0% |
For cosmetic peptide raw materials requiring N-acyl hydroxyproline, Cbz-L-hydroxyproline is first hydrogenolyzed in methanol/water 1:1 at 0.15–0.25 MPa hydrogen over 5% palladium on carbon; the isolated free hydroxyproline is then N-acylated with palmitoyl chloride under Schotten-Baumann conditions. The acylation charge is 1.05–1.15 molar equivalents of fatty acid chloride relative to hydroxyproline, with aqueous sodium hydroxide maintaining pH 9.0–10.0 and jacket temperature at 10–15 °C. Residual palmitic acid is removed by acid precipitation, and the filter cake is washed until chloride ion is below 50 ppm by silver nitrate test; vacuum drying at 40 °C prevents polymorph conversion. The hydrogenolysis catalyst is reused for no more than three consecutive batches because palladium leaching into the filtrate rises after this point, requiring re-slurrying and integrity testing of the catalyst pad.
Compliance is governed by EC 1223/2009 for cosmetic ingredients and REACH registration requirements in the EU. Nitrosamine risk is controlled by limiting secondary amine content to ≤5 ppm via LC-MS/MS, and residual methanol is controlled to ≤3000 ppm using USP <467> as a non-official release method. Terminal finished product types include palmitoyl hydroxyproline and acetyl hydroxyproline raw materials used in skin-conditioning and anti-aging cosmetic formulations; Cbz is not present in the final cosmetic raw material because the protecting group is removed before acylation.
Peptide-linker intermediates for antibody-drug conjugates and diagnostic bioconjugates frequently contain hydrazone or carbonate linkages that are incompatible with trifluoroacetic acid cleavage. In these sequences, Cbz-L-hydroxyproline is introduced at 1.0–1.1 molar equivalents per coupling step and removed by catalytic hydrogenolysis at pH 6.5–7.5, avoiding strong acid and strong base. Coupling is conducted with 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and N,N-diisopropylethylamine in dimethylformamide at 0–5 °C, with inline conductivity monitoring for endpoint detection. Free N-terminal amine is monitored by ninhydrin test, and coupling reagents are removed by cold water precipitation at 2–8 °C followed by filtration through polypropylene cloth and washing with water/acetone 4:1.
Quality requirements for this segment follow ICH Q7 and 21 CFR 211 when the conjugate is intended for pharmaceutical use; mutagenic impurities are assessed under ICH M7 for N,N-diisopropylethylamine and benzotriazole-derived residues. Residual solvent testing follows USP <467> with dimethylformamide limited to ≤880 ppm; residual palladium is controlled to ≤10 ppm. Terminal products are peptide-linker payloads, bioconjugation intermediates, and acid-labile peptide conjugates for oncology or diagnostic applications. Published data for specific marketed payload structures is limited because formulation-specific degradation thresholds are not publicly disclosed; pilot-batch stability normally requires linker integrity at 40 °C/75% RH for 4 weeks.
| Scenario | Stoichiometric range | Process parameter | Critical limit |
|---|---|---|---|
| Solution-phase peptide coupling | 1.05–1.20 molar equivalents; 1.20–1.30 for hindered N-terminal amine | Activation -15 ± 2 °C | D-allo-Hyp ≤0.3% area |
| O-silylation for organocatalyst precursor | 1.05–1.20 molar equivalents silyl chloride; 1.10–1.30 imidazole | 0–5 °C; <100 ppm water | Diastereomeric purity ≥99.0:1.0 |
| N-acylation for cosmetic raw material | 1.05–1.15 molar equivalents fatty acid chloride | pH 9.0–10.0; 10–15 °C | Chloride ≤50 ppm |
| Peptide-linker coupling | 1.0–1.1 molar equivalents per coupling | pH 6.5–7.5 hydrogenolysis; 0–5 °C coupling | No TFA exposure |
| 4-Substituted pyrrolidine building block | 1.0–1.1 molar equivalents activated Cbz-Hyp | 25–35 °C DMF displacement | Enantiomeric purity ≥99.0% area |
| Custom synthesis reagent | 1.0–1.2 molar equivalents | Microwave 50 °C for 30 min | Assay ≥98.0% |
The C4 hydroxyl of Cbz-L-hydroxyproline is activated with methanesulfonyl chloride or para-toluenesulfonyl chloride in dichloromethane at 0–5 °C using triethylamine as base. The activated intermediate is displaced by nitrogen or sulfur nucleophiles in dimethylformamide at 25–35 °C to yield 4-substituted pyrrolidine intermediates; temperatures above 10 °C during activation promote elimination to 3,4-dehydroproline, so the mesylate is quenched and transferred immediately. Stoichiometric input is 1.0–1.1 molar equivalents of activated Cbz-Hyp relative to the nucleophilic partner; potassium carbonate is preferred for thioether formation. The Cbz protecting group remains intact through displacement and is removed later by hydrogenolysis at 0.10–0.20 MPa hydrogen.
Compliance is under ICH Q7 and ICH Q11 for registered intermediates and starting materials; enantiomeric purity is measured by chiral HPLC or supercritical fluid chromatography with acceptance ≥99.0% area. Residual palladium is limited to ≤10 ppm, and residual solvents follow USP <467>. Terminal products are chiral pyrrolidine building blocks used in hepatitis C virus NS3/4A protease inhibitor synthesis and other antiviral small-molecule routes. Specific marketed drug synthesis details remain proprietary; published patent routes describe Cbz-Hyp-derived 4-substituted proline intermediates within macrocyclic protease inhibitor scaffolds.
Cbz-L-hydroxyproline is supplied in research and pilot quantities for custom synthesis of hydroxyproline-containing peptides and small-molecule libraries. Laboratory-scale solution-phase coupling typically charges 1.0–1.2 molar equivalents of the protected amino acid relative to the substrate, using microwave-assisted activation at 50 °C for 30 min in dimethylformamide. Quality release includes HPLC assay ≥98.0%, enantiomeric purity ≥99.0% area, and unknown impurities ≤1.0%; compliance obligations are limited to REACH and ISO 9001:2015 for research-grade supply. Terminal product types are custom hydroxyproline-containing peptides, chiral probes, and screening-library intermediates. Published data for specific customer configurations is limited because final use is defined outside the supplier control boundary.
Competitive CBZ-L-Hydroxyproline prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
CBZ-L-Hydroxyproline is the N-benzyloxycarbonyl-protected derivative of (2S,4R)-4-hydroxy-L-proline, supplied as a protected amino acid building block for solution-phase and fragment-based peptide synthesis. The compound is identified by CAS registry number 13504-85-3, molecular formula C13H15NO5, and molecular weight 265.26 g mol−1. In supplier documentation the product is also listed as N-Cbz-4-hydroxy-L-proline, Z-Hyp-OH, and N-carbobenzyloxy-L-hydroxyproline. The free carboxyl group at the 2 position remains available for activation, while the pyrrolidine nitrogen is masked by the benzyloxycarbonyl group. The 4R hydroxyl stereochemistry is derived from trans-4-hydroxy-L-proline and distinguishes the material from its 4S cis isomer. The Cbz group is base-stable and removable by catalytic hydrogenolysis or strong acid, which places the compound in an orthogonal protection niche relative to Fmoc-protected and Boc-protected monomers.
The release specification for peptide-synthesis-grade material typically follows the test panel in Table 1. These are not harmonized pharmacopoeial monographs; they represent the routine certificate-of-analysis parameters used by fine-chemical distributors for non-sterile peptide intermediates. Commonly stocked pack sizes are 25 g, 100 g, 500 g, and 1 kg; no standardized industry model number exists, but distributor catalog codes generally embed the abbreviation Z-Hyp-OH and the relevant stereochemical prefix. The receiving site should verify whether the supplier’s chromatographic integration method matches the system suitability requirements of USP <621> or Ph. Eur. 2.2.29.
| Parameter | Method / standard | Typical acceptance range |
|---|---|---|
| Appearance | Visual inspection, Ph. Eur. 2.2.1 | White to off-white crystalline powder |
| Purity by reversed-phase HPLC | USP <621>, Ph. Eur. 2.2.29, C18 column, UV detection at 210 nm | ≥ 98.5 area percent |
| Chiral purity | Chiral HPLC on polysaccharide column, heptane/ethanol/trifluoroacetic acid 90:10:0.1 v/v/v | ≥ 99.0 area percent |
| Specific optical rotation | Ph. Eur. 2.2.7, c = 1.0 in methanol | Reported negative value, commonly −60° to −66° |
| Water content by Karl Fischer | ISO 760 | ≤ 0.5 percent |
| Residual solvents by headspace GC | Ph. Eur. 2.4.24, ICH Q3C | Report class 3 solvents |
| Melting range | USP <741> | Commonly observed 103–108 °C |
Storage and dispensing in peptide production suites is dry, refrigerated, and light-protected. The compound is typically held at 2–8 °C in sealed amber glass or fluoropolymer-lined containers with desiccant. Karl Fischer re-analysis is recommended after container opening because the free hydroxyl group is hygroscopic; open-bench weighing at relative humidity above 60% can increase water content by 0.2–0.5 wt% within 15–30 min. For moisture-sensitive amino acid couplings using uronium reagents, this water uptake is sufficient to alter reagent stoichiometry and reduce coupling efficiency if the carboxylic acid charge is calculated from nominal dry weight.
Chiral HPLC methods for CBZ-L-Hydroxyproline use polysaccharide-based columns such as amylose tris(3,5-dimethylphenylcarbamate) with mobile phases consisting of heptane and ethanol. The method is not standardized across manufacturers; retention of the 4S cis impurity may be less than 5 min under fast gradients, so an orthogonal capillary electrophoresis or proton NMR chiral shift reagent can be used to confirm enantiomeric excess when regulatory filings require a second method. System suitability is established by injecting a mixture of the 4R and 4S isomers and requiring a resolution factor of not less than 1.5.
Activation of the free carboxyl group in CBZ-L-Hydroxyproline is usually carried out in DMF or dichloromethane at 0–5 °C. With diisopropylcarbodiimide or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, the first-formed O-acylisourea rearranges to the active ester in the presence of HOBt or HOAt. The unprotected secondary hydroxyl at the 4R position can compete as an internal nucleophile during prolonged activation; this intramolecular attack consumes activated species and lowers the isolated yield of the desired peptide bond. The side reaction is controlled by limiting the pre-activation interval to 3–8 min before addition of the incoming amine, or by maintaining the reaction jacket at −5 °C to 0 °C in a scaled glass reactor.
Production-scale peptide synthesizers with stirred glass reactors of 20 L or larger typically add DIPEA slowly over 10 min to control the coupling exotherm. If the reaction temperature rises above 5 °C, the proportion of lactonized or diketopiperazine-like by-products can increase, particularly when the C-terminal residue is hydroxyproline. Pre-activation using uronium reagents such as HATU requires 1.0 equiv relative to the carboxyl component rather than excess; excess base can abstract the α-proton and promote oxazolone formation, which is detected as an increase in the D-isomer content by chiral HPLC. The unprotected hydroxyl form avoids a subsequent silyl ether deprotection step, but it narrows the processing window. Published data for this specific configuration is limited; process development should therefore include a design-of-experiments screen across temperature, base addition time, and reagent stoichiometry before transfer to kilogram-scale batches.
Glass-lined or fluoropolymer-lined reactors are preferred because the product and its activated species are not corrosive, but trace iron from unlined stainless steel can discolor the reaction and reduce palladium catalyst life in subsequent hydrogenolysis. In a 20 L glass reactor equipped with a retreat-curve agitator and jacket thermal control, the addition of EDC hydrochloride as a solid in 4–6 portions over 15 min avoids local overheating. The slurry viscosity rises during active ester formation; an agitator torque increase of 10–20% relative to the initial DMF slurry indicates that the solution has become supersaturated and should be diluted before the amine addition.
Coupling efficiency in demanding Hyp-rich sequences is higher when the side-chain hydroxyl is protected as the tert-butyldimethylsilyl ether, because the intramolecular nucleophile is blocked; however, that derivative requires fluoride-based deprotection, which can be incompatible with acid-labile resin linkers and with certain peptide sequences. The unprotected CBZ-L-Hydroxyproline is selected when the target sequence contains no hydroxyl-sensitive coupling partners and when hydrogenolytic Cbz removal at the fragment stage is preferred over strong acid treatment.
Removal of the Cbz group from a hydroxyproline-containing peptide is most often performed by catalytic hydrogenolysis using 5% palladium on carbon or 20% palladium hydroxide on carbon under hydrogen at 1–4 bar. Methanol, ethanol, or aqueous acetic acid serve as solvents; the reaction is usually complete in 2–12 h at 20–25 °C, but the rate depends on catalyst wetting, residual sulfur compounds, and peptide aggregation. In production hydrogenators, catalyst loading is screened from 5–10 wt% wet catalyst relative to substrate. For peptides containing methionine or cysteine, palladium poisoning can arrest the reaction; in those cases Cbz removal is replaced by HBr in acetic acid with anisole as a benzyl bromide scavenger. The HBr route is faster but can acid-cleave tert-butyl ester or Boc groups if care is not taken, so it is not an orthogonal substitute in fully protected fragments.
Hydrogenolysis generates benzyl alcohol and carbon dioxide; the benzyl alcohol is removed by extraction or precipitation, and its residual level should be checked by headspace GC if the peptide intermediate is intended for later GMP processing. Because CBZ-L-Hydroxyproline is acid-stable to TFA, it can be taken through tert-butyl ester and acid-labile linker conditions, but it will not survive hydrogenation steps used to remove benzyl esters. Therefore, methyl or tert-butyl ester protection of the hydroxyproline carboxyl group is chosen when carboxyl protection must persist through Cbz hydrogenolysis.
CBZ-L-Hydroxyproline is often compared with Boc-L-hydroxyproline and Fmoc-L-hydroxyproline in peptide synthesis workflows. Boc is removed by TFA, Fmoc by piperidine or morpholine, and Cbz by hydrogenolysis or strong acid. This makes Cbz stable to both TFA and short piperidine exposure, allowing it to function as a semi-permanent protection in solution-phase peptide fragments that also contain acid- and base-labile groups. The benzyl chromophore in Cbz has lower UV intensity than the Fmoc group, so coupling and deprotection are less readily monitored at 300 nm; Cbz-protected intermediates are more commonly tracked at 214 nm or 254 nm.
| Attribute | CBZ-L-Hydroxyproline | Boc-L-Hydroxyproline | Fmoc-L-Hydroxyproline |
|---|---|---|---|
| Removal condition | H2/Pd or HBr/AcOH | TFA | piperidine or morpholine |
| Stability to TFA | stable | labile | stable |
| Stability to piperidine | stable for short cycles | stable | labile |
| UV monitoring | weak at 254 nm | not applicable | strong at 300 nm |
| Typical synthesis mode | solution-phase fragment assembly | acid-labile SPPS strategies | Fmoc/tBu SPPS |
The trans-4-hydroxy-L-proline configuration of the Cbz-protected monomer matters more in collagen-mimetic and proline-rich peptide channels than in generic peptide synthesis. Replacement of proline with (2S,4R)-4-hydroxyproline increases the thermal stability of collagen triple helices because the 4R hydroxyl preorganizes the pyrrolidine ring; the 4S cis isomer has the opposite effect. Collagen peptide literature reports shifts in melting temperature that depend on peptide length and sequence context, and published data for this specific configuration is limited outside the standard Pro-Hyp-Gly repeat models. Chiral HPLC comparison against the 4S isomer is therefore a necessary release test for any lot intended for helical peptide assembly, because even a 1.0% cis contamination can depress cooperative unfolding curves in oligomerization assays.
During purification after coupling, residual benzyl alcohol from Cbz deprotection can be removed by aqueous extraction, but residual toluene from manufacturing may be detected at trace levels. For peptide intermediates regulated under ICH Q3A and Q3C, a dedicated gas chromatographic method with headspace injection is applied. If the coupled peptide contains a C-terminal Hyp residue, aqueous wash pH should be kept between 3.0 and 4.0 to avoid precipitation of the free acid at the interface.
Solvent and water residues carried by CBZ-L-Hydroxyproline into downstream coupling reactors have a direct impact on the consumption of carbodiimide and uronium reagents. Vacuum drying at 40 °C and 10 mbar for 12 h is applied when the Karl Fischer result exceeds 0.5%. Residual ethanol, ethyl acetate, or dichloromethane from recrystallization can be reduced to below ICH Q3C Class 3 limits using this drying condition, but the product should not be dried above 50 °C because thermal stability data for this specific configuration is limited. After drying, the material is cooled under nitrogen and discharged into a desiccated double polyethylene liner; packaging under argon is common for peptide-synthesis-grade lots intended for long-term storage at 2–8 °C.
On kilogram-scale production, batch-to-batch color variation is sometimes observed after Cbz introduction. Peptide-grade lots are typically recrystallized from ethyl acetate/heptane, filtered at 0–5 °C, and washed with cold heptane to remove benzyl alcohol, dibenzyl carbonate, and trace N-benzyl impurities. The recrystallization yield can drop by 10–15% if the mother liquor is warmed above 5 °C during filtration. The isolated product is then vacuum-dried and sampled for chiral HPLC, Karl Fischer, and residual solvent analysis before release; no additional formulation additives are used unless the destination synthesis specifically requires a co-solvent to suppress caking.